GALT earnings date and last-quarter result: next report 2026-08-13, last quarter miss, P/E -8.60. Updated 2026-07-23.
Galectin Therapeutics (GALT) Research Hub
Galectin Therapeutics (GALT) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-10-26, shares last closed at 3.19 USD (0.00%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -8.60, market cap 0.24B. This hub links to the full technical, earnings and options research available for GALT.
Last updated 2026-10-26 · Source: end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 3.19 USD (0.00%) |
| 52-week range | 2.58 USD – 5.39 USD |
| Trend regime | Range |
| 14-day RSI | 29.2 (Oversold) |
| Trailing P/E | -8.60 |
| Market cap | 0.24B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-13 |
Available research for GALT
Covered Call on GALT: how it works, illustrative setup around the real 3.19 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on GALT: how it works, illustrative setup around the real 3.19 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on GALT: how it works, illustrative setup around the real 3.19 USD price, max profit/loss, breakeven and when to use it. Educational.
GALT technical analysis: range, last 3.19 USD, RSI 29.2, 52w range 2.58 USD–5.39 USD, real support/resistance. Updated 2026-10-26.
More on SniperIQ
Frequently asked questions
What sector is GALT in?
Galectin Therapeutics (GALT) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is GALT in an uptrend or downtrend?
As of 2026-10-26, GALT is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is GALT's trailing P/E ratio?
GALT's trailing P/E is -8.60, with a market cap of 0.24B. See the earnings research page for full valuation detail.
When does GALT next report earnings?
GALT is next scheduled to report earnings on 2026-08-13.